Recent Notable & Newsworthy Drug Approvals in Medical Dermatology
The past year has been an extraordinary time in drug approvals in medical dermatology, especially the approval of treatments that impact patients with skin of color, according to Dr. Andrew F. Alexis, co-chair of Skin of Color Update. Next Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. Alexis, who is also vice-chair for diversity and inclusion for the Weill Cornell Medica …
The past year has been an extraordinary time in drug approvals in medical dermatology, especially the approval of treatments that impact patients with skin of color, according to Dr. Andrew F. Alexis, co-chair of Skin of Color Update. Next Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. Alexis, who is also vice-chair for diversity and inclusion for the Weill Cornell Medica … Continue reading "Recent Notable & Newsworthy Drug Approvals in Medical Dermatology"
Get ready to explore the latest advancements in dermatology with the March issue of the Journal of Drugs in Dermatology! This edition dives deep into cutting-edge research, including AI-driven personalized hair loss treatments, the dermatologic potential of berberine, and the evolving role of social media in hair loss education. Plus, don't miss insights on acneceuticals, the skin microbiome in ec … 
At the 2025 ODAC Dermatology Conference, we were delighted to learn about alternative treatments for androgenetic alopecia (AGA), presented by Dr. Terrence Keaney, Founder and Director of SkinDC and Clinical Associate Professor of Dermatology at The George Washington University School of Medicine and Health Sciences.
In recent times, there has been an exponential growth of interest from the pat … 
The February 2025 issue of the Journal of Drugs in Dermatology brings a fresh wave of clinical insights and innovative research to the dermatology community. This edition highlights new perspectives on minoxidil adherence, groundbreaking findings in keloid and hypertrophic scar risk factors, and expert consensus on deucravacitinib for plaque psoriasis.
Readers will also discover updates on non- … 
At the forefront of the evolving treatment landscape for cutaneous squamous cell carcinoma (cSCC), Dr. David M. Miller—a board-certified internist, dermatologist, and medical oncologist at Massachusetts General Hospital—delivered a highly informative lecture on the past, present, and future of immunotherapy for cSCC at ODAC 2025. With his unique expertise across three disciplines, Dr. Miller e … 